Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review
Life · 23.09.2025 · 15 (10) · 1497
DOI: 10.3390/life15101497 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 23.09.2025. Verfasst von Alexandra Vrabie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Lupus nephritis (LN) is a major cause of mortality and morbidity in patients with systemic lupus erythematosus (SLE). Biomarkers derived from blood, urine, and multi-omics techniques are essential for enabling access to less invasive methods for LN evaluation and personalized precision medicine. Materials and Methods: The purpose of this work was to review the studies that addressed the potential role of urinary and serological biomarkers for the diagnosis, disease activity, response to treatment, and renal outcome of adult patients with LN, published over the past decade, and summarize their results with a particular emphasis being directed towards the available traditional tools.
Results
Traditional biomarkers used for the diagnosis and surveillance of LN are proteinuria, urinary sediment, estimated glomerular filtration rate (eGFR), anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-C1q, and serum complement levels. Anti-dsDNA, serum C3, and proteinuria are the conventional biomarkers with the strongest clinical evidence, with overall moderate ability in predicting LN from non-renal SLE, disease activity, renal flares, response to therapy, and prognosis. The last decade has brought significant progress in our understanding regarding the pathogenesis of LN and, consequently, several molecules, either alone or in combination panels, have emerged as potential novel biomarkers, some of them outperforming conventional biomarkers. Promising results have been suggested for urinary activated leukocyte cell adhesion molecule (ALCAM), soluble cluster of differentiation 163 (CD163), C-X-C motif chemokine ligand 10 (CXCL10), monocyte chemoattractant protein 1 (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), tumor necrosis factor-like weak inducer of apoptosis (TWEAK), and vascular cell adhesion molecule 1 (VCAM-1).
Conclusions
Despite the intensive research of the last decade, no novel biomarker has entered clinical practice, and we continue to rely on traditional biomarkers to assess non-invasively LN and guide its treatment. Novel biomarkers should be validated in multiple longitudinal independent cohorts, compared with conventional biomarkers, and integrated with renal histology information in order to optimize the management of LN patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania.
- Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania.
ORCID-Profile: Bogdan Obrișcă, Bogdan Marian Sorohan
Zitieren
APA
Vrabie, A., Obrișcă, B., Sorohan, B. M., & Ismail, G. (2025). Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review. Life, 15(10), 1497. https://doi.org/10.3390/life15101497
Vancouver
Vrabie A, Obrișcă B, Sorohan BM, Ismail G. Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review. Life. 2025;15(10):1497. doi:10.3390/life15101497
BibTeX
@article{Vrabie2025,
author = {Vrabie, Alexandra and Obrișcă, Bogdan and Sorohan, Bogdan Marian and Ismail, Gener},
title = {Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review},
journal = {Life},
year = {2025},
volume = {15},
number = {10},
pages = {1497},
doi = {10.3390/life15101497}
}
EUVIMED